Covid19 Clinical Trial
Official title:
Risk Factors, Prognosis and Findings by Computed Tomography in Patients Infected by COVID-19 and Its Association With Severity.
NCT number | NCT04577105 |
Other study ID # | 20-1177 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | April 1, 2020 |
Est. completion date | October 1, 2020 |
Verified date | October 2020 |
Source | Instituto Nacional de Cardiologia Ignacio Chavez |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
In the SARS-CoV2 pandemic, imaging studies proved its diagnostic utility to determine the
severity of lung involvement. Computed tomography (CT) is a state-of-the-art study proven to
be a highly sensitive diagnostic test complemented by RT-PCR testing to determine the disease
and the degree of severity.
In March 2020, the Dutch Society of Radiology developed a standardized assessment scheme for
COVID-19 lung disease, called CO-RADS. This system proposes a level of suspicion of pulmonary
involvement of COVID-19, based on the simple chest tomography findings. The level of
suspicion ranges from very low (CO-RADS 1) to very high (CO-RADS 5), with two additional
categories involving a technically deficient study (CO-RADS 0) and a positive RT-PCR test for
SARS -CoV-2 known before tomography (CO-RADS 6).
For its part, acute respiratory damage secondary to SARS-COV2 pneumonia causes acute
respiratory distress syndrome, which warrants immediate medical attention. During the
evaluation and triage of patients with suspected or confirmed SARS-COV2 infection, it is a
challenge for health personnel given that the severity and clinical presentation is highly
variable. The patient's risk stratification is carried out using previously established and
validated risk scales and is a fundamental tool for making clinical decisions. Some of the
risk indices and scales have been developed and used in the pandemic epicenters, such as
China and Europe. Useful for the clinician is the national early warning scale (NEWS 2),
severe disease risk assessment score (COVID-GRAM), the rapid severity index for COVID-19
(qCSI), evaluation score of Modified sequential organ failure (mSOFA), the sepsis-induced
coagulopathy score (SIC), the ROX index as a predictor of success to the high-flow nasal
cannula. The evaluation of the risk of thrombotic complications such as the Padua risk, of
cardiac complications such as QT segment prolongation, through the Tisdale risk score.
Risk stratification is essential in the current COVID-19 pandemic situation; upon admission,
the clinician will discern if the patient requires in-hospital medical treatment, the risk of
severe disease, and progression to assisted mechanical ventilation.
This work aims to establish whether the severity of the findings identified by cardiac
tomography upon admission and the risk established by the different established prognostic
indices.
Status | Completed |
Enrollment | 233 |
Est. completion date | October 1, 2020 |
Est. primary completion date | August 31, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Patients who go to the emergency department meet the criteria for a suspected, probable, or confirmed case of COVID-19 infection. - Patients who have undergone a simple chest tomography during their stay in the INC Emergency Department. - Patients whose information and data availability can be obtained through the triage's electronic clinical record carried out in the emergency department and coronary unit. - Patients with clinical data, laboratory data, oxygen saturation, and inspired oxygen fraction are necessary to evaluate prognostic indices. - Test for SARS-CoV2 infection by RT-PCR reported as positive, negative, or not performed, but with suspicion of COVID-19. - Patients who have had an arterial blood gas. Exclusion Criteria: - Patients with incomplete clinical, laboratory, blood gas parameters. - Patients in whom saturation and initial FiO2 are not reported. - Patients referred to another Hospital during their initial evaluation. |
Country | Name | City | State |
---|---|---|---|
Mexico | Instituto Nacional Ignacio Chavez | Ciudad de mexico |
Lead Sponsor | Collaborator |
---|---|
Instituto Nacional de Cardiologia Ignacio Chavez |
Mexico,
ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012 Jun 20;307(23):2526-33. doi: 10.1001/jama.2012.5669. — View Citation
Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M, De Bon E, Tormene D, Pagnan A, Prandoni P. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost. 2010 Nov;8(11):2450-7. doi: 10.1111/j.1538-7836.2010.04044.x. — View Citation
Chung M, Bernheim A, Mei X, Zhang N, Huang M, Zeng X, Cui J, Xu W, Yang Y, Fayad ZA, Jacobi A, Li K, Li S, Shan H. CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV). Radiology. 2020 Apr;295(1):202-207. doi: 10.1148/radiol.2020200230. Epub 2020 Feb — View Citation
Ding X, Xu J, Zhou J, Long Q. Chest CT findings of COVID-19 pneumonia by duration of symptoms. Eur J Radiol. 2020 Jun;127:109009. doi: 10.1016/j.ejrad.2020.109009. Epub 2020 Apr 18. — View Citation
Fan E, Brodie D, Slutsky AS. Acute Respiratory Distress Syndrome: Advances in Diagnosis and Treatment. JAMA. 2018 Feb 20;319(7):698-710. doi: 10.1001/jama.2017.21907. Review. — View Citation
Hani C, Trieu NH, Saab I, Dangeard S, Bennani S, Chassagnon G, Revel MP. COVID-19 pneumonia: A review of typical CT findings and differential diagnosis. Diagn Interv Imaging. 2020 May;101(5):263-268. doi: 10.1016/j.diii.2020.03.014. Epub 2020 Apr 3. Review. — View Citation
Helmholz HF Jr. The abbreviated alveolar air equation. Chest. 1979 Jun;75(6):748. — View Citation
Iba T, Nisio MD, Levy JH, Kitamura N, Thachil J. New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. BMJ Open. 2017 Sep 27;7(9):e017046. doi: 10.1136/bmjopen-2017-017 — View Citation
Liang W, Liang H, Ou L, Chen B, Chen A, Li C, Li Y, Guan W, Sang L, Lu J, Xu Y, Chen G, Guo H, Guo J, Chen Z, Zhao Y, Li S, Zhang N, Zhong N, He J; China Medical Treatment Expert Group for COVID-19. Development and Validation of a Clinical Risk Score to P — View Citation
Pan F, Ye T, Sun P, Gui S, Liang B, Li L, Zheng D, Wang J, Hesketh RL, Yang L, Zheng C. Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19). Radiology. 2020 Jun;295(3):715-721. doi: 10.1148/radiol.2020200370. Epub 2020 Feb 13. — View Citation
Prokop M, van Everdingen W, van Rees Vellinga T, Quarles van Ufford H, Stöger L, Beenen L, Geurts B, Gietema H, Krdzalic J, Schaefer-Prokop C, van Ginneken B, Brink M; COVID-19 Standardized Reporting Working Group of the Dutch Radiological Society. CO-RAD — View Citation
Prytherch DR, Smith GB, Schmidt PE, Featherstone PI. ViEWS--Towards a national early warning score for detecting adult inpatient deterioration. Resuscitation. 2010 Aug;81(8):932-7. doi: 10.1016/j.resuscitation.2010.04.014. — View Citation
Roca O, Caralt B, Messika J, Samper M, Sztrymf B, Hernández G, García-de-Acilu M, Frat JP, Masclans JR, Ricard JD. An Index Combining Respiratory Rate and Oxygenation to Predict Outcome of Nasal High-Flow Therapy. Am J Respir Crit Care Med. 2019 Jun 1;199 — View Citation
Sánchez-Oro R, Torres Nuez J, Martínez-Sanz G. Radiological findings for diagnosis of SARS-CoV-2 pneumonia (COVID-19). Med Clin (Barc). 2020 Jul 10;155(1):36-40. doi: 10.1016/j.medcli.2020.03.004. Epub 2020 Apr 3. English, Spanish. — View Citation
Santamarîa Herrero SA. [Alveolar-arterial gradient of oxygen in COPD patients]. An Med Interna. 2001 Mar;18(3):115-6. Spanish. — View Citation
Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, Fan Y, Zheng C. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020 Apr;20(4):425-434. doi: 10.1016/S1473-3099(20)30086-4. Epub 2020 Fe — View Citation
Song J, Tian J, Zhang L, Qu X, Qian W, Zheng B, Zhang L, Zhao J, Niu M, Zhou M, Cui L, Liu Y, Zhao M. Development and validation of a prognostic index for efficacy evaluation and prognosis of first-line chemotherapy in stage III-IV lung squamous cell carcinoma. Eur Radiol. 2019 May;29(5):2388-2398. doi: 10.1007/s00330-018-5912-2. Epub 2019 Jan 14. — View Citation
Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Proble — View Citation
Ye Z, Zhang Y, Wang Y, Huang Z, Song B. Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review. Eur Radiol. 2020 Aug;30(8):4381-4389. doi: 10.1007/s00330-020-06801-0. Epub 2020 Mar 19. Review. — View Citation
Zahorec R. Ratio of neutrophil to lymphocyte counts--rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy. 2001;102(1):5-14. English, Slovak. — View Citation
Zhou Z, Guo D, Li C, Fang Z, Chen L, Yang R, Li X, Zeng W. Coronavirus disease 2019: initial chest CT findings. Eur Radiol. 2020 Aug;30(8):4398-4406. doi: 10.1007/s00330-020-06816-7. Epub 2020 Mar 24. — View Citation
* Note: There are 21 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assessment of the level of suspicion of SARS-CoV2 infection | CO-RADS will categorize the level of suspicion of COVID-19. Very low (CO-RADS 1) to very high (CO-RADS 5), with two additional categories involving a technically deficient study (CO-RADS 0) and a positive RT-PCR test for SARS-CoV- 2 known before tomography (CO-RADS 6). | At hospital admission | |
Primary | Evaluate the severity degree of pulmonary affection by chest computed tomography | It will be a semi-quantitative assessment of lung lobe lesions' extent considering five lobes (upper right lobes, middle lobe, lower right lobe, upper left lobe, and lower left lobe). Each of these lobes, depending on their condition, is scored from 1 to 5, with 1 <5%, 2 from 5 to 25%, 3> 25 to 50%, 4 from> 50 to 75% and the number 5 greater than 75%. With this, it is grouped into mild affection from 1 to 5 points, moderate from 5 to 15 points, and greater than 15 points as severe affection | At hospital admission | |
Primary | Percentage of patients requiring endotracheal intubation | The requirement for orotracheal intubation and the start of assisted mechanical ventilation after admission will be evaluated | From admission to discharge, up to 1 week | |
Primary | Death from any cause | Patients who present fatal descent during hospitalization will be evaluated. | From admission to discharge, up to 1 week | |
Secondary | Modified Sequential Organ Failure Assessment (mSOFA) | The evaluation of multiple organ failure secondary to sepsis will be carried out using the mSOFA scale, which can predict in-hospital mortality and 30 days, with a minimum score of 0-7 that translates mortality of 0% and a score greater than 11 translates mortality of 58%. | At hospital admission | |
Secondary | Sepsis-induced coagulopathy (SIC) | The sepsis-induced coagulopathy score scale (SIC) refers to the diagnosis of coagulopathy when the score is greater than 4 or the INR is greater than or equal to 3. | At hospital admission | |
Secondary | National Early Warning Scale (NEWS 2) | A score of 0-4 confers a low risk; on the contrary, a score of more than 7 gives a high risk. | At hospital admission | |
Secondary | COVID-GRAM severe illness risk score | It establishes three risk groups: the mild one with a risk of critical illness of less than 1.7% and the high risk of more than 40.4%. | At hospital admission | |
Secondary | Rapid Severity Index for COVID-19 (qCSI) | A score less than or equal to 3 gives a low risk with a critical illness risk of 4%, while a score of 10-12 gives a high risk and a critical illness probability of 57%. | At hospital admission | |
Secondary | Neutrophil-Lymphocyte Ratio (NLR) | A ratio of 6-8 translates mild physiological stress, while a ratio of more than 18 a severe physiological stress level. | At hospital admission | |
Secondary | Alveolar-arterial gradient of oxygen | The gradient Aa O2 = [(FiO2) × (Atmospheric pressure - Pressure of H2O) - (PaCO2 / 0.8)] - PaO2 of ABG is calculated and a normal gradient with age is estimated with the following formula: Estimate of normal gradient = (Age / 4) + 4. The gradient is increased in conditions such as ARDS, PE, and cardiac failure. | At hospital admission | |
Secondary | Berlin Criteria for Acute Respiratory Distress Syndrome | Required criteria (must have all three of the following): Timing within 1 week of clinical insult or new/worsening respiratory symptoms, Chest XR shows bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules Respiratory failure not fully explained by cardiac failure/fluid overload Risk factor (one of the following): Risk factor for ARDS present (e.g. pneumonia, trauma, sepsis, pancreatitis). Objective assessment (Echo) excludes hydrostatic edema. Severity (based on oxygenation, select one of the following): Mild: PaO2/FiO2 >200 to =300 mmHg with PEEP OR CPAP =5 cm H2O, Moderate: PaO2/FiO2 >100 to =200 mmHg with PEEP =5 cm H2O and Severe: PaO2/FiO2 =100 mmHg with PEEP =5 cm H2O |
At hospital admission |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |